Protherics Plc - Report of Foreign Issuer (6-K)
14/08/2008 6:23pm
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
14 August 2008
PROTHERICS PLC
(Translation of Registrant’s Name Into
English)
The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
X
Form
40-F
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 191(b)(7):
Indicate by check mark whether the registrant by
furnishing the information contained in this form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
of 1934.
Yes
No
X
If “Yes” is marked, indicate below the
file number assigned to the registrant in connection with Rule 12g3-2(b):
82-
.
The Registrant is furnishing a copy of its
announcements as reported to the Company Announcements Office of the London Stock
Exchange.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned,
thereunto duly
authorized
.
|
|
|
|
|
|
|
|
|
|
|
PROTHERICS
PLC
|
|
|
|
|
|
|
|
|
|
Date: 14 August
2008
|
|
By:
|
|
/s/ Rolf
Soderstrom
|
|
|
|
|
|
Rolf
Soderstrom
|
|
|
|
|
|
Finance
Director
|
London, UK;
Brentwood, TN, US;
In accordance with Rule 2.10 of
the City Code on Takeovers and Mergers (the "Code"), Protherics
confirms that at the close of business on 13 August 2008, it has
342,159,034 ordinary shares of 2 pence each in issue and admitted to
trading on the London Stock Exchange under the UK ISIN code
GB0007029209.
The ISIN number above
corrects that cited in the Rule 2.4 announcement issued by the
Company on 13 August 2008.
For further
information please contact:
|
|
|
|
|
|
Rolf Soderstrom, Finance Director
|
|
Nick Staples, Director of Corporate
Affairs
|
|
|
|
|
Jefferies International
Ltd.
|
|
|
|
|
|
|
|
Nomura Code Securities
Ltd.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dealing Disclosure
Requirements
Under the provisions of Rule
8.3 of the Code, if any person is, or becomes, interested"
(directly or indirectly) in 1% or more of any class of "relevant
securities" of
, all "dealings" in any
"relevant securities" of that company (including by means of an
option in respect of, or a derivative referenced to, any such
"relevant securities") must be publicly disclosed by no later than
3.30 pm (London time) on the London business day following the date
of the relevant transaction. This requirement will continue until
the date on which the offer becomes, or is declared, unconditional
as to acceptances, lapses or is otherwise withdrawn or on which the
"offer period" otherwise ends. If two or more persons act together
pursuant to an agreement or understanding, whether formal or
informal, to acquire an "interest" in "relevant securities"
of
, they will be deemed to be a
single person for the purpose of Rule 8.3.
Under the provisions of Rule
8.1 of the Code, all "dealings" in "relevant securities"
of
by a potential offeror,
or by
, or by any of their
respective "associates", must be disclosed by no later than 12.00
noon (London time) on the London business day following the date of
the relevant transaction.
A disclosure table, giving
details of the companies in whose "relevant securities" "dealings"
should be disclosed, and the number of such securities in issue,
can be found on the Takeover Panel's website at
www.thetakeoverpanel.org.uk
"Interests in securities"
arise, in summary, when a person has long economic exposure,
whether conditional or absolute, to changes in the price of
securities. In particular, a person will be treated as having an
"interest" by virtue of the ownership or control of securities, or
by virtue of any option in respect of, or derivative referenced to,
securities. Terms in quotation marks are defined in the Code, which
can also be found on the Panel's website. If you are in any doubt
as to whether or not you are required to disclose a "dealing" under
Rule 8, you should consult the Panel.
accept responsibility
for the information contained in this announcement. To the best of
the knowledge and belief of the Directors of
, who have taken all
reasonable care to ensure that this is the case, this information
is in accordance with the facts and does not omit anything likely
to affect its import. This announcement does not constitute an
offer or invitation to purchase or subscribe for any securities of
the Company.
Jefferies International
Limited, which is authorised and regulated in the UK by The
Financial Services Authority, is acting exclusively
for
and no one else in
connection with the
matters referred to in this
announcement
and, accordingly, will not be
responsible to anyone other than
for providing the
protections afforded to customers of Jefferies International
Limited or for providing advice in relation to
the
matters referred to in this
announcement
(LSE: PTI, NASDAQ:
PTIL) is a leading international biopharmaceutical company focused
on specialist products for critical care and cancer.
has produced two FDA
approved biologics for critical care use which are currently sold
in the US: CroFab™, a North American pit viper antivenom and
DigiFab™, a digoxin antidote.
reported revenues of
£26.1 million for its year ended 31 March 2008 and a strong
cash balance of £37.7 million.
The Company's strategy is to
use the revenues generated from its marketed and out-licensed
products to help fund the advancement of its broad, late stage
pipeline.
has two major
development opportunities in its portfolio. CytoFab™ is being
developed by AstraZeneca, for the treatment of severe sepsis,
following a major licensing deal announced in December 2005.
AstraZeneca is conducting an additional phase 2 programme following
changes to the commercial manufacturing process. A new formulation
of Angiotensin Therapeutic Vaccine, for the treatment of
hypertension,
also has four novel
products being developed in a range of cancer indications where it
intends to undertake the sales and marketing in the US and/or the
EU.
With headquarters in London,
the Company has approximately 300 employees across its operations
in the UK, US and Australia.
For further information
visit:
This document contains
forward-looking statements that involve risks and uncertainties
including with respect to
products under
development and the progress and completion of clinical
trials.
Although we believe that the
expectations reflected in such forward-looking statements are
reasonable at this time, we can give no assurance that such
expectations will prove to be correct. Given these uncertainties,
readers are cautioned not to place undue reliance on such
forward-looking statements. Actual results could differ materially
from those anticipated in these forward-looking statements due to
many important
' Annual Report on Form 20-F
and other reports filed from time to time with the U.S. Securities
and Exchange Commission.
We do not undertake to update
any oral or written forward-looking statements that may be made by,
or on behalf of,
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
